Monday June 26th 2017

Archive for April, 2015

Blood–brain barrier and neurological diseases

Blood–brain barrier and neurological diseases

Abstract The blood–brain barrier (BBB), an anatomically and functionally unique structure, maintains the homeostasis of the central nervous system (CNS) by maintaining the optimal ionic environment for neuronal function and transporting trophins or nutrients, as well as [Read More]

Restless legs syndrome in psoriasis: an unexpected comorbidity

Restless legs syndrome in psoriasis: an unexpected comorbidity

Conclusions Our findings indicate an increased frequency of RLS in patients with psoriasis, suggesting screening patients with psoriasis for the presence of RLS as a well-treatable co-morbidity. (Source: European Journal of Dermatology) [Read More]

Autoimmune polyendocrine syndrome type 3 in a multiple sclerosis patient

Autoimmune polyendocrine syndrome type 3 in a multiple sclerosis patient

We present the case of a 37‐year‐old Japanese man diagnosed with MS and Graves’ disease at 22 years‐of‐age. Interferon‐β‐1b therapy, which he had previously discontinued for 10 years, was restarted for MS at 35 years‐of‐age. After the therapy, he [Read More]

 Page 1 of 219  1  2  3  4  5 » ...  Last » 

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]